Alexa P. Kollmeier

1.6k citations

61 papers · 1.1k indexed · 2 hit papers · h-index 15

Co-authors: Xie L. Xu Elizabeth C. Hsia Shihong Sheng Prasheen Agarwal Yanli Zhuang Philip J. Mease Bei Zhou Proton Rahman
Topics: Psoriasis: Treatment and Pathogenesis (45 papers)Spondyloarthritis Studies and Treatments (37 papers)Rheumatoid Arthritis Research and Therapies (24 papers)
Cited by: Rheumatology Hematology Immunology
Journals: The Lancet Journal of Allergy and Clinical Immunology Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States United Kingdom Canada

In The Last Decade

Alexa P. Kollmeier

54 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

2020 242 citations Philip J. Mease, Proton Rahman et al. profile →
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

2020 233 citations Atul Deodhar, Philip Helliwell et al. profile →

Peers

Countries citing papers authored by Alexa P. Kollmeier

Since Specialization

Citations

This map shows the geographic impact of Alexa P. Kollmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexa P. Kollmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexa P. Kollmeier more than expected).

Fields of papers citing papers by Alexa P. Kollmeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexa P. Kollmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexa P. Kollmeier. The network helps show where Alexa P. Kollmeier may publish in the future.

Co-authorship network of co-authors of Alexa P. Kollmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Alexa P. Kollmeier. A scholar is included among the top collaborators of Alexa P. Kollmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexa P. Kollmeier. Alexa P. Kollmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study 2025 ·Annals of the Rheumatic Diseases ·Philip J. Mease,Christopher T. Ritchlin,Laura C. Coates,Alexa P. Kollmeier,Bei Zhou,(unknown),(unknown),(unknown),(unknown),Soumya D. Chakravarty,Proton Rahman,Désirée van der Heijde	0
2	Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis 2024 ·Clinical Rheumatology ·Proton Rahman,Iain B. McInnes,Atul Deodhar,Georg Schett,Phillip J. Mease,M. Shawi,J. Daniel,Jonathan Sherlock,Alexa P. Kollmeier,Xie L. Xu,Shihong Sheng,Christopher T. Ritchlin,Dennis McGonagle	0
3	Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis 2024 ·Arthritis & Rheumatology ·Stefan Siebert,Laura C. Coates,Georg Schett,S. P. Raychaudhuri,(unknown),Sheng Gao,Loqmane Seridi,Soumya D. Chakravarty,M. Shawi,F. Lavie,(unknown),(unknown),Alexa P. Kollmeier,Xie L. Xu,Proton Rahman,Philip J. Mease,Atul Deodhar	4
4	Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study 2024 ·RMD Open ·Laura C. Coates,Laure Gossec,(unknown),M. Shawi,Emmanouil Rampakakis,Natalie J. Shiff,Alexa P. Kollmeier,Xie L. Xu,Peter Nash,Philip J. Mease,Philip Helliwell	5
5	POS0227 SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS 2023 ·Annals of the Rheumatic Diseases ·Signe Holm Nielsen,Anne‐Christine Bay‐Jensen,Peder Frederiksen,M.A. Karsdal,M. Shawi,(unknown),Alexa P. Kollmeier,(unknown),Sheng Gao	0
6	Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies 2023 ·ACR Open Rheumatology ·Dennis McGonagle,Iain B. McInnes,Atul Deodhar,Georg Schett,M. Shawi,Soumya D. Chakravarty,Alexa P. Kollmeier,Xie L. Xu,Shihong Sheng,Stephen Xu,Christopher T. Ritchlin,Proton Rahman,Phillip J. Mease	4
7	Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials 2023 ·ACR Open Rheumatology ·Stefan Siebert,Kristen Sweet,Christopher T. Ritchlin,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,Loqmane Seridi,Qingxuan Song,Sheng Gao,(unknown),Michelle Miron	2
8	Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis 2023 ·Drug Safety ·Bruce Strober,Laura C. Coates,Mark Lebwohl,Atul Deodhar,(unknown),(unknown),Alexa P. Kollmeier,Megan Miller,Yanli Wang,Shu Li,Soumya D. Chakravarty,Daphne Chan,M. Shawi,Ya‐Wen Yang,(unknown),Proton Rahman	31
9	Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study 2023 ·Rheumatology and Therapy ·Philip J. Mease,Dafna D. Gladman,Denis Poddubnyy,Soumya D. Chakravarty,M. Shawi,Alexa P. Kollmeier,Xie L. Xu,Stephen Xu,Atul Deodhar,Xenofon Baraliakos	11
10	Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment 2023 ·Clinical Rheumatology ·Philip J. Mease,Alice B. Gottlieb,Alexis Ogdie,Iain B. McInnes,Soumya D. Chakravarty,Emmanouil Rampakakis,Alexa P. Kollmeier,Xie L. Xu,M. Shawi,F. Lavie,Mitsumasa Kishimoto,Proton Rahman	1
11	Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study 2023 ·ACR Open Rheumatology ·Christopher T. Ritchlin,Atul Deodhar,Wolf‐Henning Boehncke,Enrique R. Soriano,Alexa P. Kollmeier,Xie L. Xu,(unknown),M. Shawi,(unknown),Shihong Sheng,Philip Helliwell	9
12	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies 2022 ·RMD Open ·Christopher T. Ritchlin,Philip J. Mease,Wolf‐Henning Boehncke,John Tesser,Elena Schiopu,Soumya D. Chakravarty,Alexa P. Kollmeier,Xie L. Xu,M. Shawi,(unknown),Shihong Sheng,Yanli Wang,Stephen Xu,Joseph F. Merola,Iain B. McInnes,Atul Deodhar	18
13	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis 2022 ·Lara D. Veeken ·Laura C. Coates,Christopher T. Ritchlin,Laure Gossec,Philip Helliwell,Proton Rahman,Alexa P. Kollmeier,Xie L. Xu,M. Shawi,Chetan S. Karyekar,(unknown),W. Noël,Shihong Sheng,Yanli Wang,Stephen Xu,Philip J. Mease	11
14	AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis 2022 ·Annals of the Rheumatic Diseases ·Philip J. Mease,(unknown),(unknown),(unknown),M. Shawi,Ya‐Wen Yang,Megan Miller,Alexa P. Kollmeier,X. L. Xu,Jingxue Yu,(unknown),(unknown),(unknown),Iain B. McInnes	1
15	POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB 2022 ·Annals of the Rheumatic Diseases ·Peter Nash,Christopher T. Ritchlin,Proton Rahman,M. Shawi,(unknown),(unknown),Alexa P. Kollmeier,X. L. Xu,(unknown),(unknown),Saakshi Khattri,Enrique R. Soriano,D. Mcgonagle	1
16	POS1044 GUSELKUMAB PROVIDES CONSISTENT AND DURABLE PAIN IMPROVEMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF 2 PHASE 3, RANDOMIZED, CONTROLLED CLINICAL TRIALS 2022 ·Annals of the Rheumatic Diseases ·Peter Nash,Lai‐Shan Tam,(unknown),Ying Ying Leung,(unknown),(unknown),(unknown),M. Shawi,Alexa P. Kollmeier,(unknown),(unknown)	1
17	POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS 2022 ·Annals of the Rheumatic Diseases ·Philip J. Mease,A.B. Gottlieb,Iain B. McInnes,Proton Rahman,Alexa P. Kollmeier,X. L. Xu,(unknown),(unknown),M. Shawi,Soumya D. Chakravarty,(unknown),D. van der Heijde	1
18	Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis 2021 ·Arthritis & Rheumatology ·Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,(unknown),Shihong Sheng,M. Shawi,Soumya D. Chakravarty,Désirée van der Heijde,Philip J. Mease	66
19	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced 2021 ·RMD Open ·Christopher T. Ritchlin,Philip Helliwell,Wolf‐Henning Boehncke,Enrique R. Soriano,Elizabeth C. Hsia,Alexa P. Kollmeier,Soumya D. Chakravarty,(unknown),Ramanand A. Subramanian,Xie L. Xu,Qing Zuraw,Shihong Sheng,(unknown),Prasheen Agarwal,Bei Zhou,Yanli Zhuang,M. Shawi,Chetan S. Karyekar,Atul Deodhar	50
20	Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis 2020 ·Arthritis & Rheumatology ·Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Soumya D. Chakravarty,Xie L. Xu,Ramanand A. Subramanian,Prasheen Agarwal,Shihong Sheng,(unknown),Bei Zhou,Yanli Zhuang,Désirée van der Heijde,Philip J. Mease	56

About Alexa P. Kollmeier

Alexa P. Kollmeier is a scholar working on Rheumatology, Immunology and Hematology, having authored 61 papers that have together received 1.1k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (45 papers), Spondyloarthritis Studies and Treatments (37 papers) and Rheumatoid Arthritis Research and Therapies (24 papers). The work is most often cited by research in Rheumatology (761 citations), Hematology (451 citations) and Immunology (832 citations). Alexa P. Kollmeier has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Xie L. Xu, Elizabeth C. Hsia, Shihong Sheng, Prasheen Agarwal, Yanli Zhuang, Philip J. Mease, Bei Zhou, Proton Rahman, Iain B. McInnes and Désirée van der Heijde. Their work appears in journals such as The Lancet, Journal of Allergy and Clinical Immunology and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact